• by Sayed Ashraful Emdad
• 2026-07-01

EAACI 2026: Recent Advances in the Management of Allergic Diseases

EAACI 2026: Recent Advances in the Management of Allergic Diseases

June 12�15, 2026 | Istanbul, T�rkiye

Symptom Burden Among Patients Interested in Grass Pollen Allergen Immunotherapy

Presenter: S. Allekotte

This prospective multicentre observational study examined the clinical burden of seasonal grass pollen allergy in individuals considering allergen immunotherapy (AIT). Researchers followed 479 participants with confirmed grass pollen sensitization throughout the 2025 pollen season using electronic symptom diaries.

Disease severity was evaluated using the Combined Symptom and Medication Score (CSMS) together with visual analogue scale (VAS) assessments. Nearly two-thirds of participants (63.3%) experienced moderate-to-severe disease based on CSMS values, indicating that many patients could be appropriate candidates for AIT according to current recommendations. Symptom severity reflected both clinical manifestations and medication requirements. Asthma symptoms were also common, with many participants requiring asthma medication during the observation period.

Key takeaway: Most patients seeking grass pollen AIT demonstrated clinically significant disease severity, supporting the potential role of immunotherapy in appropriately selected individuals.

House Dust Mite Sublingual Immunotherapy for Vernal Keratoconjunctivitis with Allergic Rhinitis

Presenter: M. Ahmed

A clinical case described the successful use of house dust mite (HDM) sublingual immunotherapy (SLIT) in a 15-year-old patient with severe vernal keratoconjunctivitis (VKC) accompanied by persistent allergic rhinitis.

Following confirmation of HDM sensitization through skin prick testing, daily HDM SLIT was initiated. Clinical improvement became noticeable within two weeks, while both ocular and nasal symptoms were well controlled by six weeks. Conventional allergy medications were gradually withdrawn, and after more than four months of follow-up, symptom control was maintained using SLIT alone without reported safety concerns.

Key takeaway: HDM SLIT may provide sustained disease control and reduce dependence on multiple medications in appropriately sensitized patients with VKC and allergic rhinitis.

Real-World Performance of Mepolizumab in Severe Asthma Patients With and Without Allergic Rhinitis

Presenter: J. Dominguez-Ortega

The TYREX real-world study investigated whether coexisting allergic rhinitis influences treatment outcomes with mepolizumab in severe asthma.

A total of 446 patients received mepolizumab for periods ranging from one year to over five years. Clinical improvements included marked reductions in blood eosinophils, lower FeNO levels, fewer asthma exacerbations, improved lung function, and better asthma control. Similar benefits were observed regardless of whether patients also had allergic rhinitis, and remission rates were comparable between groups.

Key takeaway: Mepolizumab maintained long-term clinical effectiveness in severe asthma irrespective of concomitant allergic rhinitis.

International Expert Consensus on the Role of Allergen Immunotherapy

Presenter: G.W. Canonica

Using a Delphi consensus methodology, an international panel of allergy specialists developed recommendations regarding the use of allergen immunotherapy for allergic rhinitis and rhinoconjunctivitis.

Forty-seven consensus statements were evaluated, with every statement achieving the predefined agreement threshold. Experts recognized AIT as the only currently available treatment capable of producing sustained disease remission after therapy completion and emphasized the importance of identifying suitable patients early during disease management.

Key takeaway: The consensus supports integrating allergen immunotherapy into standardized treatment pathways to achieve long-term disease control.

House Dust Mite Subcutaneous Immunotherapy in Polysensitized Allergic Rhinitis

Presenter: Z. Pan

This retrospective multicentre analysis assessed the effectiveness of HDM subcutaneous immunotherapy (SCIT) among allergic rhinitis patients sensitized to multiple inhalant allergens.

Following 12�36 months of treatment, nearly 70% of patients experienced meaningful improvement in perennial symptoms. Clinical response differed according to accompanying allergen sensitizations, and elevated HDM- and mould-specific IgE concentrations were associated with a lower probability of treatment success. A predictive model incorporating these biomarkers demonstrated good ability to identify potential non-responders.

Key takeaway: HDM SCIT benefits many polysensitized patients, although treatment response varies according to individual sensitization profiles.

Phase II Evaluation of the Anti-ST2 Monoclonal Antibody TQC2938

Presenter: Y. Zhang

This multicentre randomized placebo-controlled trial evaluated TQC2938 in adults with moderate-to-severe seasonal allergic rhinitis that remained inadequately controlled despite conventional therapy.

Although the overall study population did not achieve statistically significant improvement in nasal symptom scores compared with placebo, the 420 mg dose demonstrated significant benefit in patients with lower baseline eosinophil counts. The treatment was generally well tolerated, with no serious treatment-related safety concerns reported.

Key takeaway: TQC2938 may represent a promising treatment option for selected patients with seasonal allergic rhinitis, particularly those with lower eosinophilic inflammation.

Phase I Study of a Biodegradable Microneedle Patch for House Dust Mite Immunotherapy

Presenter: K.H. Park

Researchers evaluated DF19001, a biodegradable transdermal microneedle patch designed to deliver HDM allergens for immunotherapy.

The phase I trial demonstrated favorable tolerability, with mainly mild local skin reactions and no serious adverse events. Although significant improvements in nasal symptoms were not observed compared with placebo, immunologic analyses revealed dose-dependent increases in allergen-specific IgG4, indicating biological activity and induction of immune responses.

Key takeaway: DF19001 showed an encouraging safety profile and measurable immunologic effects, supporting continued investigation in larger clinical trials.

Overall Highlights from EAACI 2026
A large proportion of patients with seasonal allergic rhinitis remain suitable candidates for allergen immunotherapy.
Both sublingual and subcutaneous allergen immunotherapy continue to demonstrate meaningful clinical benefits in selected patient populations.
Mepolizumab provides sustained long-term benefit in severe asthma regardless of concomitant allergic rhinitis.
International experts continue to support allergen immunotherapy as the only disease-modifying treatment capable of achieving long-lasting remission after therapy completion.
Emerging biologic agents and innovative delivery technologies, including anti-ST2 therapy and microneedle patch immunotherapy, show promising potential for future allergy management.

Read More